Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 215 (TMEM215) is a two-pass transmembrane protein localized mainly to the endoplasmic reticulum membrane and is highly expressed in endothelial cells as well as some neuronal tissues[1][2]. TMEM215 plays a critical, nonredundant role in regulating endothelial cell survival by inhibiting apoptosis: its knockdown results in pronounced endothelial cell death, leading to vessel regression and impaired angiogenesis[1][2]. Mechanistically, TMEM215 forms a complex with BiP and BIK to prevent excessive Ca2+ transfer from the ER to mitochondria via mitochondria-associated membranes (MAMs), thereby limiting mitochondrial Ca2+ overload and activation of apoptotic pathways[1]. In mouse models, loss of TMEM215 in endothelial cells disrupts vascular remodeling and inhibits tumor angiogenesis and metastasis by promoting endothelial apoptosis and reducing vessel density[1]. TMEM215 is not currently considered a pharmacological or clinical therapeutic target, and no drugs are known to modulate its function[1][2][3].
modulation of endothelial apoptosis mediated by TMEM215 expression, via BiP and BIK interactions at the ER-mitochondria interface[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 215 (TMEM215).